What are the next steps for a patient with cytology results showing scattered squamous and urothelial cells with degenerative changes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Cytology Showing Scattered Squamous and Urothelial Cells with Degenerative Changes

The next step for a patient with cytology showing scattered squamous and urothelial cells with degenerative changes should be a complete urologic evaluation including cystoscopy to rule out bladder cancer.

Understanding the Significance of These Cytology Findings

Degenerative changes in urothelial and squamous cells on cytology represent a non-specific finding that requires further investigation. While these changes alone are not diagnostic of malignancy, they cannot be dismissed as benign without additional workup, especially given that:

  • Urothelial carcinoma is the most common histologic subtype in the urinary tract (>90% of urinary tract tumors) 1
  • Squamous cells may represent normal contamination from the lower urinary tract or vagina in women, but could also indicate squamous differentiation in urothelial carcinoma 1
  • Degenerative changes can sometimes mask underlying cellular atypia that may be associated with malignancy

Recommended Diagnostic Algorithm

1. Initial Evaluation

  • Office cystoscopy to directly visualize the bladder mucosa for any suspicious lesions 1
  • Complete upper tract imaging (one of the following):
    • CT urography (preferred approach) 1
    • Intravenous pyelogram (IVP)
    • Retrograde pyelogram
    • Renal ultrasound with retrograde pyelogram
    • MRI urogram

2. If Cystoscopy Shows a Lesion

  • Schedule transurethral resection of bladder tumor (TURBT) with bimanual examination under anesthesia 1
  • If the lesion appears solid (sessile), high-grade, or suggests muscle invasion, obtain CT scan of abdomen and pelvis before TURBT 1
  • TURBT should include adequate sampling of muscle within the area of the tumor to assess for invasion 1

3. If Cystoscopy is Normal but Cytology Remains Concerning

  • Consider selected mapping biopsies of the bladder 1
  • Evaluate upper tract with cytology and consider ureteroscopy 1
  • Consider TUR biopsy of the prostate in men 1

4. If All Evaluations Are Negative

  • Follow-up with repeat cytology and cystoscopy in 3 months 1

Important Considerations

Potential Pitfalls

  1. Misinterpreting degenerative changes as benign: Degenerative changes can sometimes mask underlying cellular atypia that may be associated with malignancy 2, 3

  2. Overlooking squamous cells: The presence of dysplastic squamous cells in urine cytology may indicate high-grade urothelial carcinoma with squamous differentiation, which occurs mainly in high-grade urothelial carcinoma with invasion 4

  3. Ignoring upper tract sources: Remember that urothelial tumors can originate in the renal pelvis (8%) and ureter/urethra (2%) 1

Special Populations

  • Women: Consider gynecologic sources of squamous cells, as atypical squamous cells in urine may rarely originate from gynecologic malignancies 5, 6

  • Patients with hematuria: Microscopic hematuria is the most common presenting symptom of bladder cancer and should increase suspicion for malignancy even with equivocal cytology 1

By following this systematic approach to evaluating patients with degenerative changes in urothelial and squamous cells, you can ensure appropriate diagnosis and management while minimizing the risk of missing significant pathology.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.